Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P62854
UPID:
RS26_HUMAN
Alternative names:
40S ribosomal protein S26
Alternative UPACC:
P62854; P02383; P70394; Q06722; Q3MHD8; Q6IRY4
Background:
Small ribosomal subunit protein eS26, also known as 40S ribosomal protein S26, plays a crucial role in the synthesis of proteins within the cell. As a component of the small ribosomal subunit, it is pivotal in translating mRNA into amino acid sequences, thereby facilitating the production of proteins essential for cellular function and growth.
Therapeutic significance:
The protein is linked to Diamond-Blackfan anemia 10, a rare disorder characterized by anemia, congenital anomalies, and an increased risk of malignancy. Understanding the role of Small ribosomal subunit protein eS26 could open doors to potential therapeutic strategies for this condition.